1. Home Page
  2. For Cancer Researchers
  3. Research
  4. Research Labs
  5. Ranganathan Lab
  6. Discoveries and Publications
Ranganathan Lab

Discoveries, Awards and Publications

Learn about the research projects currently underway at The Ranganathan Lab.

    Dr. Ranganathan is an accomplished, world-recognized cancer research specialist with an impressive catalogue of breakthroughs, discoveries, awards and publications. These include:

    • 2022-2023: Careers in Immunology Fellowship, American Association of Immunologists
    • 2022-2026: Research Scholar Award, American Cancer Society
    • 2019-2021: K12 Paul Calabresi Career Development Award
    • 2018-2020: Junior Faculty Award, Pelotonia Intramural Research Program
    • 2017-2018: Young Investigator Award, Leukemia Research Foundation
    • 2013-2016: Special Fellow Award, Leukemia & Lymphoma Society
    • 2011-2013: Pelotonia Post-Doctoral Fellowship Award

    Selected Publications

    Kumar R, Ranganathan P. PRMT5: Splicing up tolerance. J Clin Invest. 2024 Oct 15;134(20):e185701. [PubMed]

    Neidemire-Colley L, Khanal S, Braunreiter KM, Gao Y, Kumar R, Snyder KJ, Weber MA, Surana S, Toirov O, Karunasiri M, Duszynski ME, Chi M, Malik P, Kalyan S, Chan WK, Naeimi Kararoudi M, Choe HK, Garzon R, Ranganathan P. CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model. Blood Adv. 2024 Feb 27;8(4):947-958. [PubMed]

    Neidemire-Colley L, Robert J, Ackaoui A, Dorrance AM, Guimond M, Ranganathan P. Corrigendum: Role of endothelial cells in graft-versus-host disease. Front Immunol. 2023 Jan 4;13:1125035.

    Neidemire-Colley L, Robert J, Ackaoui A, Dorrance AM, Guimond M, Ranganathan P. Role of endothelial cells in graft-versus-host disease. Front Immunol. 2022 Nov 23;13:1033490. [PubMed]

    Snyder KJ, Choe HK, Gao Y, Sell NE, Braunreiter KM, Zitzer NC, Neidemire-Colley L, Kalyan S, Dorrance AM, Keller A, Mihaylova MM, Singh S, Sehgal L, Bollag G, Ma Y, Powell B, Devine SM, Ranganathan P. Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease. Front Oncol. 2021 Oct 15;11:760789. [PubMed]

    Snyder K, Zitzer NC, Gao Y, Choe HK, Sell NE, Neidemire-Colley L, Ignaci A, Kale C, Devine RD, Abad MG, Pietrzak M, Wang M, Lin H, Zhang YW, Behbehani GK, Jackman JE, Garzon R, Vaddi K, Baiocchi RA, Ranganathan P. PRMT5 regulates T cell interferon response and is a target for acute graft versus host disease. JCI Insight. 2020 Apr 23;5(8). [PubMed]

    Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R, Ranganathan P. MicroRNA-155 modulates acute graft-versus-host disease by impacting T-cell expansion, migration, and effector function. J Immunol. 2018 Jun 15;200(12):4170-4179. [PubMed]

    Ranganathan P, Ngankeu A, Zitzer NC, Leoncini P, Yu X, Casadei L, Challagundla K, Reichenbach DK, Garman S, Ruppert AS, Volinia S, Hofstetter J, Efebera YA, Devine SM, Blazar BR, Fabbri M, Garzon R. Serum miR-29a is upregulated in acute Graft versus Host Disease and activates dendritic cells through TLR binding. J Immunol. 2017 Mar 15;198(6):2500-2512. [PubMed]

    Ranganathan P, Kashyap T, Yu X, Meng X, Lai T-H, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Blum W, Sampath D, Landesman Y, Garzon R. XPO1 Inhibition Using Selinexor Synergizes With Chemotherapy in Acute Myeloid Leukemia (AML) by Targeting DNA Repair and Restoring Topoisomerase to the Nucleus. Clin Can Res. 2016 Dec 15;22(24):6142-6152. [PubMed]

    Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood. 2015 Apr 23;125(17):2689-92. [PubMed]

    Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012 Aug 30;120(9):1765-73. Plenary paper in issue. [PubMed]

    Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana’ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 2012 May 17;119(20):4786-97. [PubMed]

    View all publications

    Collaboration with Other Ohio State Labs and Research Teams

    The Ranganathan Lab research scientists regularly collaborate with teams at other institutions as well as those within the OSUCCC – James. By collaborating with scientists who complement the team’s strengths, skills and expertise, the team sees multiple paths forward to further successes.

    Their collaborations include those with:

    • The OSUCCC – James Blood and Marrow Transplant Program, where nationally and internationally recognized cancer researchers conduct research in all aspects of transplant biology and immunology to understand the mechanisms of post-transplant complications and to improve patient survival outcomes.
    • The OSUCCC – James Leukemia and Hematologic Malignancies Program, where experts focus on the etiology, pathogenesis, prognosis and treatment of leukemia and hematologic diseases.
    • The Pelotonia Institute for Immuno-Oncology, a nationally acclaimed research initiative that focuses on harnessing the body’s immune system to fight cancer at all levels.

    Additionally, the Ranganathan Lab research scientists collaborate with various OSUCCC – James scientists from other research teams who share unique perspectives and novel techniques and who offer new approaches to understanding and analyzing lymphoma.

    Collaborative researchers include:

    For more information on the Ranganathan Lab team, collaborations, opportunities and lab-specific inquiries, please contact Malith.Karunasiri@osumc.edu.